JP5863640B2 - 免疫複合体の精製 - Google Patents

免疫複合体の精製 Download PDF

Info

Publication number
JP5863640B2
JP5863640B2 JP2012508634A JP2012508634A JP5863640B2 JP 5863640 B2 JP5863640 B2 JP 5863640B2 JP 2012508634 A JP2012508634 A JP 2012508634A JP 2012508634 A JP2012508634 A JP 2012508634A JP 5863640 B2 JP5863640 B2 JP 5863640B2
Authority
JP
Japan
Prior art keywords
cft
gah
support
buffer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012508634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525407A (ja
JP2012525407A5 (https=
Inventor
マーク スナイダー
マーク スナイダー
Original Assignee
バイオ−ラッド ラボラトリーズ インコーポレーティッド
バイオ−ラッド ラボラトリーズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5863640(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バイオ−ラッド ラボラトリーズ インコーポレーティッド, バイオ−ラッド ラボラトリーズ インコーポレーティッド filed Critical バイオ−ラッド ラボラトリーズ インコーポレーティッド
Publication of JP2012525407A publication Critical patent/JP2012525407A/ja
Publication of JP2012525407A5 publication Critical patent/JP2012525407A5/ja
Application granted granted Critical
Publication of JP5863640B2 publication Critical patent/JP5863640B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2012508634A 2009-04-29 2010-04-28 免疫複合体の精製 Expired - Fee Related JP5863640B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17389609P 2009-04-29 2009-04-29
US61/173,896 2009-04-29
PCT/US2010/032724 WO2010126979A1 (en) 2009-04-29 2010-04-28 Purification of immunoconjugates

Publications (3)

Publication Number Publication Date
JP2012525407A JP2012525407A (ja) 2012-10-22
JP2012525407A5 JP2012525407A5 (https=) 2013-06-06
JP5863640B2 true JP5863640B2 (ja) 2016-02-16

Family

ID=43030882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508634A Expired - Fee Related JP5863640B2 (ja) 2009-04-29 2010-04-28 免疫複合体の精製

Country Status (5)

Country Link
US (1) US8481694B2 (https=)
EP (1) EP2424875B1 (https=)
JP (1) JP5863640B2 (https=)
CA (1) CA2759502C (https=)
WO (1) WO2010126979A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5881744B2 (ja) * 2011-02-02 2016-03-09 バイオ−ラッド ラボラトリーズ インコーポレーティッド アルカリ溶液でのアパタイトの表面中和方法
US9442050B2 (en) 2012-02-14 2016-09-13 Bio-Rad Laboratories, Inc. Reducing pH excursions in ion exchange chromatography using displacing counter ions
GB201310028D0 (en) * 2013-06-05 2013-07-17 Algeta Asa Pharmaceutical preparation
CN108348604B (zh) * 2015-09-08 2022-04-29 沃特世科技公司 用于分析抗体-药物缀合物的多维色谱方法
US11661438B2 (en) * 2015-12-21 2023-05-30 Pfizer, Inc. Purification of antibody drug conjugates using a sodium phosphate gradient
WO2017165745A1 (en) * 2016-03-24 2017-09-28 The Trustees Of Columbia University In The City Of New York Selectively and fully cleavable fluorescent probes for sequential, itrative immunostaining
US10934366B2 (en) 2016-09-29 2021-03-02 Bio-Rad Laboratories, Inc. Protein-nanoparticle conjugate purification methods
US20210130396A1 (en) * 2017-08-30 2021-05-06 Ares Trading S.A. Method for purifying proteins

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
PT1308456E (pt) * 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AU2003201824A1 (en) * 2002-01-03 2003-07-24 Smithkline Beecham Corporation Methods for preparing immunoconjugates
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2336172B1 (en) 2003-10-27 2014-12-10 Wyeth LLC Removal of high molecular weight aggregates using hydroxyapatite chromatography
US20060160998A1 (en) 2005-01-19 2006-07-20 Suk Roelf J Methods for isolation and purification of fluorochrome-antibody conjugates
EP3539572A1 (en) * 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
WO2007081851A2 (en) * 2006-01-06 2007-07-19 Millipore Corporation Affinity chromatography matrices and methods of making and using the same
US20100234577A1 (en) * 2006-06-14 2010-09-16 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
US7999085B2 (en) * 2007-01-09 2011-08-16 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers

Also Published As

Publication number Publication date
CA2759502C (en) 2021-02-09
JP2012525407A (ja) 2012-10-22
EP2424875A1 (en) 2012-03-07
US20100280228A1 (en) 2010-11-04
US8481694B2 (en) 2013-07-09
EP2424875B1 (en) 2016-01-06
EP2424875A4 (en) 2012-10-31
WO2010126979A1 (en) 2010-11-04
CA2759502A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
JP5863640B2 (ja) 免疫複合体の精製
CN114127059B (zh) 大环螯合剂及其使用方法
Maruani et al. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
Adumeau et al. Site-specifically labeled immunoconjugates for molecular imaging—part 2: peptide tags and unnatural amino acids
FI87532C (fi) Monoklonala antikroppar mot metallkelat
US5807879A (en) Biotinidase-resistant biotinylated compound and methods of use thereof
EP3603663A1 (en) Method for preparing antibody-drug conjugate
KR20190029684A (ko) 고체-상 고정화된 미생물 트랜스글루타미나제 mtg 및 용액 중 mtg를 사용한 항체 리신 잔기에의 부위-특이적 접합
CA2835298A1 (en) Pretargeting kit for imaging or therapy comprising a trans - cyclooctene dienophile and a diene
WO2005086775A2 (en) Lumen-exposed molecules and methods for targeted delivery
Kirley et al. Selective disulfide reduction for labeling and enhancement of Fab antibody fragments
AU732510B2 (en) Boron neutron capture therapy using pre-targeting methods
Westerlund et al. Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting
Sarrett et al. Lysine-directed site-selective bioconjugation for the creation of radioimmunoconjugates
Myrhammar et al. Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting
JPH06507918A (ja) ｉｎ　ｖｉｖｏ　結合対プレターゲティング
IE67320B1 (en) Cross-linked antibodies and processes for their preparation
EP2988785B1 (en) Method of synthesising adcs using affinity resins
JP2017537975A (ja) 親和性樹脂を用いるＡＤＣｓ合成方法
CA2389386A1 (en) Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents
Wilbur et al. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies
Frost et al. In vitro evaluation of avidin antibody pretargeting using 211At‐labeled and biotinylated poly‐L‐lysine as effector molecule
US10744211B2 (en) Trifunctional and completely clearable specific targeting agents and methods thereof
Zhu et al. Pretargeted nuclear imaging and radioimmunotherapy based on the inverse electron-demand Diels-Alder reaction
Crauwels et al. Effect of different nanobody characteristics on the kidney retention of radiometal labeled nanobodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150925

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151222

R150 Certificate of patent or registration of utility model

Ref document number: 5863640

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees